CCAFU Recommendations 2013: Prostate cancer

• Published in: Progrès en urologie (Paris) Vol. 23 Suppl 2; p. S69
• Main Authors: Salomon, L, Bastide, C, Beuzeboc, P, Cormier, L, Fromont, G, Hennequin, C, Mongiat-Artus, P, Peyromaure, M, Ploussard, G, Renard-Penna, R, Rozet, F, Azria, D, Coloby, P, Molinié, V, Ravery, V, Rebillard, X, Richaud, P, Villers, A, Soulié, M
• Format: Journal Article
• Language: French
• Published: France 01.11.2013
• Subjects: Humans; Male; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - therapy; Traitement; Treatment; Cancer de la prostate; Diagnostic; Diagnosis; Prostate cancer; Recommandations; Guidelines
• ISSN: 1166-7087
• DOI: 10.1016/S1166-7087(13)70048-4

The sub Comittee prostate of the CCAFU established guidelines for diagnostic, treatment, evaluation and standart of care of prostate cancer. Guidelines 2010 were updated based on systematic literature search performed by the sub-Comittee in Medline and PubMed databases to evaluate references, levels of evidence and grade of recommandation. Pathological examination of the tissue specimens was defined specifically for Gleason score according to ISP 2005 recommandations. Prostate and pelvis RMN became the reference in terms of radiological exam. Individual and early diagnosis of prostate cancer was defined and role of PSA was precised. Active surveillance became one of the standart of care of low-risk tumors, radical prostatectomy remained one of the options for all risk group tumors, length of hormonotherapy in association with radiotherapy was precised according to the risk group. Side effects of hormonotherapy treament needed specific supervision ; hormonotherapy had no indication in case of non metastatic tumors and intermittent hormonotherapy in metastatic tumors. New hormonal drugs in pre and post chemotherapy and bone target drugs opened new therapeutics pathways. From 2010 to 2013, standarts of care of prostate cancer were modified because of results of prospective studies and new therapeutics. They allowed precise treatments for each specific clinical situation. In the future, multidisciplinary treatments for high risk tumors, time of adjuvant treatment and sequencies of new hormonal treatment had to be defined.